Insmed’s Brinsupri (brensocatib) became the first FDA-approved treatment specifically for non-cystic fibrosis bronchiectasis (NCFB), a chronic lung disorder afflicting approximately 500,000 U.S. patients. This first-in-class DPP1 inhibitor targets neutrophilic inflammation, aiming to reduce exacerbations and preserve lung function. The approval follows positive phase 3 data demonstrating Brinsupri’s efficacy and safety in adults and adolescents. Insmed expects significant commercial uptake, projecting multibillion-dollar sales as filings in Europe, the U.K., and Japan are underway. Meanwhile, competitors are pursuing DPP1 inhibitors targeting similar indications, indicating growing interest in this novel mechanism.